Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated (Ligand) is a biotechnology company that operates with a business model focused on developing or acquiring revenue generating assets and coupling them with a lean corporate cost structure. The Company's technology CAPTISOL is a formulation technology that has enabled seven United States Food and Drug Administration (FDA) approved products including Kyprolis and Noxafil-IV and is being developed in several clinical-stage partner programs. The Company is engaged in the development of product candidates indicated for the treatment of diseases, such as hepatitis, multiple myeloma, muscle wasting, Alzheimer’s disease, dyslipidemia, diabetes, anemia, epilepsy, focal segmental glomerulosclerosis (FSGS) and osteoporosis.
Type
Public
HQ
San Diego, US
Employees
85 (est)
Ligand Pharmaceuticals is headquartered in San Diego, US

Key People at Ligand Pharmaceuticals

David J. Mangelsdorf

David J. Mangelsdorf

Team Member
John L. Higgins

John L. Higgins

CEO
John P. Sharp

John P. Sharp

CFO
Ronald M. Evans

Ronald M. Evans

Team Member
Richard Heyman

Richard Heyman

Vice President of Research

Ligand Pharmaceuticals Locations

San Diego, US

Ligand Pharmaceuticals Metrics

Ligand Pharmaceuticals Summary

Market capitalization

$2.19 B

Closing share price

$106
Ligand Pharmaceuticals's latest market capitalization is $2.19 B.

Ligand Pharmaceuticals Market Value History

100% of current employees of Ligand Pharmaceuticals are male.

Ligand Pharmaceuticals News

Ligand Pharmaceuticals Company Life

You may also be interested in